NEWYou can now listen to Fox News articles!
Moderna has set a broad timeline to deliver a variant-specific COVID-19 vaccine booster a few days after asking the Food and Drug Administration (FDA) for permission to use its vaccine for children.
“We announced a few weeks ago a new, variant-specific booster that we have tested and we have an additional candidate, our lead candidate, in testing now, which I think will be even more superior,” Moderna Chief Medical It said Officer Paul Burton during an appearance on “Face the Nation.”
“We are confident that by the fall of this year, we should have large quantities of the new booster vaccine that will protect against omicron and other variants and truly protect Americans and people around the world as we enter the fall of 2022.”
COVID VACCINES FOR AMERICA’S YOUNGEST CHILDREN: FDA ISSUES JUNE MEETINGS
The FDA set a deadline for June for drug manufacturers to submit a formula for variant-specific vaccines. Doses of modified vaccines could cost the U.S. government between $ 5 billion and $ 12 billion, The New York Times reported.
The modern timeline could allow them to meet this deadline if the test runs smoothly and does not reveal any problems in the current wording.
CHINA’S ‘ZERO-COVID’ RESTRICTIONS UNDERSTAND 1. MAY HOLIDAY TRAVEL
Modern has also recently filed applications to the FDA for the youngest children ages 6 or younger.
“The data in the study is complete, and typically what we then do is package the data electronically for the FDA so they can perform their own reviews, their own analyzes,” Burton said. “It will go in on May 9, but they have the data they need now to begin.”
CHARLIE CRIST SAYS HE IS “OPEN” TO MASK THE MANDATE, TO LIST COVID AS A KEY QUESTION IN PURCHASE AGAINST DESANTIS
The vaccine is 37% effective for children aged 2 to 5 years and 51% effective for children under 2 years. The lower efficiency, Burton argued, is due to the strong virulence of the omicron variant.
“What it means for parents or caregivers is that if they give the Moderna vaccine to these young children, they would largely halve the risk of children getting symptomatic COVID,” “I know that 50% is often lower than what we “is used to seeing with our vaccine, but that’s because this study was conducted under omicron.”
CLICK HERE TO GET THE FOX NEWS APP
“When we look at the UK data released last week … right there we see a vaccine efficacy of 50%, but when we look at the vaccine efficacy against hospitalization it is 89-95%, so therefore I think we can be very reassured and very sure of this result. “
Right now, only children age 5 or older can be vaccinated in the United States using rival Pfizer’s vaccine.
Fox News’ Julia Musto contributed to this report.